Last reviewed 2026-04-20 · How we verify

GnRH analog (gnrh-analog)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Hot flashes/flushes
• Pain - Joint
• Fatigue (asthenia, lethargy, malaise)
• Insomnia
• Sweating (diaphoresis)
• Vaginal dryness
• Mood alteration - depression
• Nausea
• Libido
• Osteoporosis
• Pain - Vagina
• Hypertension

Key clinical trials

• A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
• A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer (PHASE1, PHASE2)
• Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (PHASE2)
• A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (PHASE2)
• Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (PHASE2)
• Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
• Body Composition Assessment in Transgender Population.
• Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• GnRH analog CI brief — competitive landscape report
• GnRH analog updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI